756 related articles for article (PubMed ID: 20656475)
1. Metformin: taking away the candy for cancer?
Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
[TBL] [Abstract][Full Text] [Related]
2. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
3. [Metformin--new treatment strategies for gynecologic neoplasms].
Milewicz T; Kiałka M; Mrozińska S; Ociepka A; Krzysiek J
Przegl Lek; 2013; 70(2):81-4. PubMed ID: 23879009
[TBL] [Abstract][Full Text] [Related]
4. Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
Goodwin PJ; Stambolic V
Breast; 2011 Oct; 20 Suppl 3():S31-5. PubMed ID: 22015290
[TBL] [Abstract][Full Text] [Related]
5. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
6. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.
Ben Sahra I; Regazzetti C; Robert G; Laurent K; Le Marchand-Brustel Y; Auberger P; Tanti JF; Giorgetti-Peraldi S; Bost F
Cancer Res; 2011 Jul; 71(13):4366-72. PubMed ID: 21540236
[TBL] [Abstract][Full Text] [Related]
7. Metformin and cancer: licence to heal?
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Investig Drugs; 2010 Aug; 19(8):913-7. PubMed ID: 20557275
[TBL] [Abstract][Full Text] [Related]
8. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
Wysocki PJ; Wierusz-Wysocka B
Expert Rev Mol Diagn; 2010 May; 10(4):509-19. PubMed ID: 20465505
[TBL] [Abstract][Full Text] [Related]
9. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
Hosono K; Endo H; Takahashi H; Sugiyama M; Uchiyama T; Suzuki K; Nozaki Y; Yoneda K; Fujita K; Yoneda M; Inamori M; Tomatsu A; Chihara T; Shimpo K; Nakagama H; Nakajima A
Mol Carcinog; 2010 Jul; 49(7):662-71. PubMed ID: 20564343
[TBL] [Abstract][Full Text] [Related]
10. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
11. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.
Bo S; Ciccone G; Rosato R; Villois P; Appendino G; Ghigo E; Grassi G
Diabetes Obes Metab; 2012 Jan; 14(1):23-9. PubMed ID: 21812892
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of metformin in breast cancer: involvement of the immune system?
Schott S; Bierhaus A; Schuetz F; Beckhove P; Schneeweiss A; Sohn C; Domschke C
Cancer Immunol Immunother; 2011 Sep; 60(9):1221-5. PubMed ID: 21681370
[TBL] [Abstract][Full Text] [Related]
13. Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review.
Ahn HK; Lee YH; Koo KC
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198356
[TBL] [Abstract][Full Text] [Related]
14. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.
Zakikhani M; Dowling R; Fantus IG; Sonenberg N; Pollak M
Cancer Res; 2006 Nov; 66(21):10269-73. PubMed ID: 17062558
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo anti-melanoma action of metformin.
Janjetovic K; Harhaji-Trajkovic L; Misirkic-Marjanovic M; Vucicevic L; Stevanovic D; Zogovic N; Sumarac-Dumanovic M; Micic D; Trajkovic V
Eur J Pharmacol; 2011 Oct; 668(3):373-82. PubMed ID: 21806981
[TBL] [Abstract][Full Text] [Related]
16. Metformin in cancer: translational challenges.
Dowling RJ; Niraula S; Stambolic V; Goodwin PJ
J Mol Endocrinol; 2012 Jun; 48(3):R31-43. PubMed ID: 22355097
[TBL] [Abstract][Full Text] [Related]
17. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
Dowling RJ; Zakikhani M; Fantus IG; Pollak M; Sonenberg N
Cancer Res; 2007 Nov; 67(22):10804-12. PubMed ID: 18006825
[TBL] [Abstract][Full Text] [Related]
18. [Anti-cancer activity of metformin: new perspectives for an old drug].
Beck E; Scheen AJ
Rev Med Suisse; 2010 Sep; 6(260):1601-7. PubMed ID: 20853715
[TBL] [Abstract][Full Text] [Related]
19. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects.
Pierotti MA; Berrino F; Gariboldi M; Melani C; Mogavero A; Negri T; Pasanisi P; Pilotti S
Oncogene; 2013 Mar; 32(12):1475-87. PubMed ID: 22665053
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
Goodwin PJ; Stambolic V; Lemieux J; Chen BE; Parulekar WR; Gelmon KA; Hershman DL; Hobday TJ; Ligibel JA; Mayer IA; Pritchard KI; Whelan TJ; Rastogi P; Shepherd LE
Breast Cancer Res Treat; 2011 Feb; 126(1):215-20. PubMed ID: 20976543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
